(Reuters) – the Bayer laboratory reported that its drug
against cancer regorafenib improved the possibilities of
survival in patients with a type of gastrointestinal tumor
and avoided the condition worsen.
The trial in finals, with 199 patients, showed that you a
the cancer of Bayer and the best care drug combination
backup went on the survival of patients with
gastrointestinal stromal tumors (GIST for its acronym in
English) metastatic, compared to the intake of a pill
placebo and better palliative care.
The trial included only patients whose disease had
progressed despite prior treatment.
Bayer said it plans to seek approval in United States
for the use of regorafenib as the GIST treatment
metastatic. Onyx Pharmaceuticals is the trading partner
American for regorafenib.
